Results 81 to 90 of about 28,157 (212)
Comparative effectiveness and safety of homologous two-dose ChAdOx1 versus heterologous vaccination with ChAdOx1 and BNT162b2: a cohort analysis [PDF]
, 2021 Daniel Prieto‐Alhambra +11 more
openalex +1 more source
Cellular Immune Response Induced by mRNA Vaccines Against SARS‐CoV‐2
Immunity, Inflammation and Disease, Volume 14, Issue 3, March 2026.SARS‐CoV‐2 vaccine induces cellular immune response. T‐cells play a protective role for COVID‐19. ABSTRACT The disease caused by SARS‐CoV‐2 is known as COVID‐19, and it can range from mild symptoms to severe clinical manifestations, including respiratory failure, pneumonia, and organ failure. Since its emergence in 2019, more than 7 million deaths have
Valentina Tovar +4 more
wiley +1 more source
Drug Product Development of Lipid Nanoparticle‐Based mRNA Therapeutics and Vaccines
WIREs Nanomedicine and Nanobiotechnology, Volume 18, Issue 2, March/April 2026.Overview of the development path from an mRNA–lipid nanoparticle (LNP) concept to a licensed drug product, covering LNP design, manufacturing process development, formulation, and analytical characterization. ABSTRACT Lipid nanoparticles (LNP) are currently the most relevant non‐viral delivery systems for mRNA and occasionally for smaller nucleic acids
Gideon Kersten +4 more
wiley +1 more source
Association Between the BNT162b2 Messenger RNA COVID-19 Vaccine and the Risk of Sudden Sensorineural Hearing Loss [PDF]
, 2022 Yoav Yanir +4 more
openalex +1 more source
Sex Differences in Response to Viral Vector Vaccines—Implications for Future Vaccine Design
Immunological Reviews, Volume 338, Issue 1, March 2026.ABSTRACT Vaccination represents one of the most impactful public health achievements, preventing 3.5 to 5 million deaths annually according to estimates of the World Health Organization. Yet, recent outbreaks of emerging and reemerging infectious diseases highlight the need for rapid and strategic vaccine development using vaccine platforms ...
Ilka Grewe +2 more
wiley +1 more source
Cardiovascular Adverse Events Reported from COVID-19 Vaccines: A Study Based on WHO Database
International Journal of General Medicine, 2021 Rimple Jeet Kaur,1 Siddhartha Dutta,1 Jaykaran Charan,1 Pankaj Bhardwaj,2 Ankita Tandon,3 Dharamveer Yadav,4 Salequl Islam,5 Mainul Haque6 1Department of Pharmacology, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India; 2Department of ...
Jeet Kaur R +7 more
doaj
Scientific Reports, 2023 In this single-center observational study with 1,206 participants, we prospectively evaluated SARS-CoV-2-antibodies (anti-S RBD) and vaccine-related adverse drug reactions (ADR) after basic and booster immunization with BNT162b2- and ChAdOx1-S-vaccines ...
Simon Dedroogh +10 more
doaj +1 more source
Advanced Science, Volume 13, Issue 7, 3 February 2026.Current SARS‐CoV‐2 vaccines generate short‐lived, strain‐specific immunity. A polymeric TLR7 agonist nanoparticle (TLR7‐NP) adjuvant enhances lymph node targeting and promotes early and sustained germinal center responses toward conserved S2 epitopes of the spike protein.
Sijin Huang +12 more
wiley +1 more source
BMC Medicine, 2022 Background In view of accumulating case reports of thyroid dysfunction following COVID-19 vaccination, we evaluated the risks of incident thyroid dysfunction following inactivated (CoronaVac) and mRNA (BNT162b2) COVID-19 vaccines using a population-based
Carlos King Ho Wong +14 more
doaj +1 more source